Peritransplantation Use of Ruxolitinib in Myelofibrosis

Uroosa Ibrahim, Giulia Eva Maria Petrone, John Mascarenhas, Alla Keyzner

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


Ruxolitinib is an oral JAK1/2 inhibitor that is approved for use in patients with intermediate and high-risk myelofibrosis (MF) based on its proven spleen and symptom burden reduction. Its impact on hematopoietic stem cell transplantation (HSCT) outcomes is largely unknown, however. A significant number of patients proceeding to HSCT have been treated with ruxolitinib, and the specifics of its peritransplantation use vary widely in the published literature. Here we review the currently published data and experience to guide management of patients with MF on ruxolitinib proceeding to HSCT.

Original languageEnglish
Pages (from-to)2177-2180
Number of pages4
JournalBiology of Blood and Marrow Transplantation
Issue number12
StatePublished - Dec 2020


  • Allogeneic transplant
  • HSCT
  • Myelofibrosis
  • Ruxolitinib


Dive into the research topics of 'Peritransplantation Use of Ruxolitinib in Myelofibrosis'. Together they form a unique fingerprint.

Cite this